COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy.
Cesar Martins da CostaZenaide Silva de SouzaAlessandra Corte Real SalguesGuilherme HaradaPedro Paulo Marino Rodrigues AyresDaniela Bulhões Vieira NunesArtur KatzRodrigo Ramella MunhozPublished in: Immunotherapy (2020)
Background: Little is known about the 2019 novel coronavirus disease (COVID-19) course and outcomes in patients receiving immunotherapy. Here we describe a metastatic Merkel cell carcinoma patient with a severe acute respiratory syndrome coronavirus 2 infection while receiving pembrolizumab. Case presentation: A 66-year-old man, with a metastatic Merkel cell carcinoma receiving pembrolizumab, presented with fever. Chest computed tomography (CT) showed pulmonary ground-glass opacities, suggesting viral or immuno-related etiology. On day 7, the patient was hospitalized due to dyspnea and worsening of the radiological findings. Real time polymerase chain reaction (RT-PCR) testing confirmed COVID-19. The patient developed acute respiratory distress syndrome and acute kidney injury. Hydroxychloroquine was administered for 5 days, but discontinued after supraventricular extrasystoles. Clinical improvement allowed the patient's discharge after 81 days of hospitalization. Conclusion: A careful evaluation of oncologic patients receiving immunotherapy during the COVID-19 pandemic is of utmost importance.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- case report
- computed tomography
- acute respiratory distress syndrome
- acute kidney injury
- squamous cell carcinoma
- small cell lung cancer
- prostate cancer
- pulmonary hypertension
- positron emission tomography
- palliative care
- adipose tissue
- skeletal muscle
- radical prostatectomy
- contrast enhanced
- minimally invasive
- epidermal growth factor receptor
- pet ct
- weight loss